
Commentary|Podcasts|May 23, 2022
Pharmacy Focus: Oncology Edition - PARP Inhibitors in Ovarian Cancer
Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.
Advertisement
In the second episode of Pharmacy Focus: Oncology Edition, Kirollos Hanna, PharmD, BCPS, BCOP, discussed how PARP inhibitors have changed the treatment landscape of ovarian cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
ACIP Votes to End Universal Hepatitis B Vaccination Recommendation for Infants
3
American Cancer Society Updates Cervical Cancer Screening Guidelines to Include Self-Collection for HPV Testing
4
Daratumumab Boosts Depth and Durability of Response After ASCT, Offering Clear Guidance for Pharmacist Counseling
5

















































































































































































































